La interrupción precoz del tratamiento triple con telaprevir de la hepatitis crónica C por efecto adverso grave no presupone necesariamente el fracaso del tratamiento

Virolés Torrent, Silvia; López Nuñez, Carmen; Hombrados Verde, Manoli; Figa Francesch, Montserrat; Acero Fernández, Doroteo; Ferri Iglesias, María José; Louvriex Freire, René.
Gastroenterol. hepatol. (Ed. impr.) ; 38(2): 78-81, feb. 2015. tab
Artículo en Español | IBECS (España) | ID: ibc-133025

Documentos relacionados

  1. Severe Acute Exacerbation After Cessation of Nucleos(t)ide Analog for Chronic Hepatitis B: A Real-World Study of Routine Practice.
  2. Predictors of early treatment discontinuation in a cohort of patients treated with boceprevir-based therapy for hepatitis C infection.
  3. Reasons for nonuse of antiviral treatment in patients with chronic hepatitis C infection and thrombocytopaenia: a retrospective chart review from five European countries.
  4. Withdrawing or withholding treatments in health care rationing: an interview study on ethical views and implications.
  5. The Path More Easily Reversed: Postponed Withholding at Borderline Viability.
  6. Ethics as Usual? Unilateral Withdrawal of Treatment in a State of Exception.
  7. [LIMITATION OF THE THERAPEUTIC EFFORT: A CLINICAL PERSPECTIVE].
  8. Interferon-alpha induced psoriasis in a teenager.
  9. Reactivation of peritoneal and pleural tuberculosis during hepatitis C treatment with direct-acting antivirals.
  10. [Discontinuing disease-modifying therapies in multiple sclerosis].